You can buy or sell VYGR and other stocks, options, ETFs, and crypto commission-free!
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. Read More The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 7
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -2.53% and 73.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for
Wall Street expects a year-over-year decline in earnings on higher revenues when Voyager Therapeutics (VYGR) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
Simply Wall StApr 30
Investors Who Bought Voyager Therapeutics (NASDAQ:VYGR) Shares Three Years Ago Are Now Up 79%
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! One simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger returns, and build a portfolio ourselves. For example, Voyager Therapeutics, Inc. (NASDAQ:VYGR) shareholders have seen the share price rise 79% over three years, well in excess of the market return (41%, not including dividends). However, more recent returns haven’t been as ...
Expected Aug 6, After Hours